11 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
27 Mar 24
Regulation FD Disclosure
4:26pm
Primary Endpoint ZETA-1 Phase 2 Study Design and Demographics N = 103 14
ETDRS monocular severity scale1 Binocular person-level scale1 Moderately
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
BID Randomization
ZETA-1: Baseline Demographics and Systemic Characteristics Well-Balanced Across Arms ZETA-1 Clinical Trial APX3330 n=51 Placebo n … Blood Pressure (mmHg) mean 82 80 Heart Rate (beats/min) mean 77 76 Hemoglobin A1C (%)mean 8.4 8.3 Body Mass Index (kg/m^2)mean 31 31 Demographics DRSS
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
APX3330 600mg/day (BID) Placebo BID Randomization
21 ZETA-1: Baseline Demographics and Systemic Characteristics Well-Balanced Across Arms ZETA-1 … proliferative diabetic retinopathy) 1 (2%) 4 (8%) 65 or Higher (Moderate to severe prolif. DR) 6 (12%) 5 (10%) Demographics Key Visual Metrics Good Visual Acuity
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
4 Nov 22
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
4:39pm
Consultants. KOL. The discussion highlighted the unmet need and current treatment landscape for DR/DME and included new data on study demographics and 24
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
14 Oct 22
Regulation FD Disclosure
11:32am
)
ZETA-1 Trial: Demographics and Masked Safety Data Presented by: Caroline Baumal, MD Caroline Baumal, MD University of Toronto
Baseline Characteristics … for ZETA-1 Trial Typical Demographics for Diabetic Population Source: ZETA-1 Demographics and Baseline Characteristics Parameter Total N = 103 Age
8-K
EX-99.2
j7f qp2i471fiv
19 May 22
Regulation FD Disclosure
7:43am
8-K
EX-99.1
laa1szxmpf
19 May 22
Regulation FD Disclosure
7:43am
8-K
EX-99.1
i96h0 oerxw
29 Mar 22
Regulation FD Disclosure
8:25am
8-K
EX-99.1
7nv60o ylkbktj
31 Jan 22
Regulation FD Disclosure
9:53am
8-K
EX-99.1
lzg tcz89l62tg
30 Jun 21
Regulation FD Disclosure
9:17am
PRER14A
v8qst92l41sys1aprvtk
7 Feb 05
Preliminary revised proxy
12:00am
- Prev
- 1
- Next